Pfizer Inc. / Coley Pharmaceutical Group Inc.

TLR-9 agonist immunotherapy platform (oncology, vaccine adjuvants, infectious disease)

Disease Overview

Coley Pharmaceutical was a Wellesley, MA biotech that pioneered Toll-like receptor (TLR) agonists—synthetic CpG oligonucleotides that stimulate innate immune pathways for use as cancer immunotherapy, vaccine adjuvants, and treatments for hepatitis C, asthma, and allergy. The lead asset PF-3512676 (CpG 7909, ProMune) was a TLR-9 agonist Pfizer had licensed from Coley in 2005.

Competitive Landscape

By late 2007, the TLR-agonist field had suffered a major setback: Pfizer and Coley discontinued the Phase 3 NSCLC program for PF-3512676 in combination with chemotherapy after futility analyses showed no survival benefit, just months before Pfizer announced the acquisition. Despite the lead-asset failure, Pfizer still paid $8/share (~$164M, vs. Coley's prior ~$3 close) to gain the broader TLR-7/8/9 platform and the VaxImmune adjuvant franchise. Competing immune-stimulant platforms included Idera Pharmaceuticals (TLR-9 IMO compounds), Dynavax (CpG TLR-9 program ultimately approved as HEPLISAV-B in 2017), and 3M's TLR-7 imiquimod (Aldara) for actinic keratosis. The deal aligned with Pfizer's vaccine-portfolio expansion (later anchored by Prevnar) and Alzheimer's immunotherapy interests, though no Coley-originated therapeutic ever reached approval, and most internal Coley programs were eventually discontinued. The acquisition is broadly viewed as an example of platform-bet M&A at a steep premium following primary-asset failure.